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CHAPTER ONE

INTRODUCTION

1.1

The Central Dogma of Molecular Biology
The central dogma of molecular biology describes the flow of genetic material from a

nucleic acid sequence to an amino acid sequence (Crick, 1958). In this process,
deoxyribonucleic acid (DNA) is transcribed to ribonucleic acid (RNA), and then RNA is
irreversibly translated to a protein. Transcription is the synthesis of a complementary
RNA chain from a template DNA strand (Crick, 1970). This process is referred to as
transcription because the four-base nucleic acid language of DNA containing G, C, A,
and T are copied, or transcribed, into the four-base nucleic acid language of RNA, with
the expectation that T is replaced with U. RNA polymerase uses one DNA strand as a
template to synthesize RNA by incorporating complementary ribonucleotides into the
growing RNA chain (Lodish et al., 2013 pp. 124-130). The second step of the central
dogma is the translation of RNA to a protein (Crick, 1970). During translation, or protein
synthesis, the four-base nucleic acid language of RNA is translated into the 20 amino
acid language of proteins (Lodish et al., 2013 pp. 136-144). Translation involves the use
of ribosomes, which are protein synthesizing machines composed of RNA and protein.
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Ribosomes facilitate the elongation of nascent protein chains by attaching the amino
acids that correspond to the RNA template (Ramakrishnan, 2002; Lodish et al, 2013 pp.
136-144).
1.2

Toxin-Antitoxin Systems
Toxin-Antitoxin (TA) systems are small genetic systems present in many bacterial

genomes (Van Melderen, 2010). These systems are theorized to act as stress-response
elements that regulate metabolism in response environmental and nutritional stress
(Pandy and Gerdes, 2005). Bacterial TA systems were originally discovered on large,
low copy plasmids; however, multiple copies of TA systems have been found on
chromosomes (Jensen and Gerdes, 1995; Pandy and Gerdes, 2005). Because they are
found on both chromosomes and plasmids, TA systems are thought to be a part of the
flexible genome. This term refers to a set of genes that have been integrated from mobile
genetic elements, such as plasmids, and are present in distant bacterial species but are not
conserved within isolates belonging to the same bacterial species. While the role of
chromosomally-encoded TA systems is not yet fully understood, plasmid-encoded TA
systems help ensure plasmid stability in growing bacterial populations
(Van Melderen and De Bast, 2009).
Plasmid-encoded TA systems generally consist of closely linked genes that
encode a stable toxin and a labile antitoxin (Gerdes, 2000). The toxin can be deleterious
to the host cell, while the antitoxin inhibits the lethal action of the toxin by inhibiting the
expression of the toxin or sequestering the toxin in a complex (Guglielmini and Van
Melderen, 2011). For instance, in type II systems the antitoxin protein binds the toxin
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protein and neutralizes its toxicity by forming a proteic complex
(Yamaguchi et al., 2011).
These systems are referred to as addiction modules because they cause the host to
become addicted to the continued presence of the plasmid by promoting the death of
plasmid-free daughter cells as seen in Figure 1.1 (Yarmolinsky, 1995). The instability of
the antitoxin is an essential component for the inhibition and activation of the toxin
(Jensen and Gerdes, 1995). In the presence of the plasmid, the level of gene expression is
typically autoregulated by the active protein products, ensuring that a steady level of the
toxin and antitoxin is maintained (Magnuson et al., 1996). While the antitoxin levels are
maintained, it inhibits the harmful effects of the toxin through complex formation
(Hayes and Sauer, 2003). However, in the absence of the plasmid, daughter cells inherit
a pool of activated gene products, but the labile antitoxin is degraded by host-encoded
proteases (Gerdes, 2000). With no new antitoxin synthesis, the antitoxin levels are
depleted in the cell while the level of free toxin rises, leading to cell death (Hayes and
Sauer, 2003). This killing, which prevents the growth of plasmid-free progeny that are
segregated from the parent cells, is referred to as post-segregational killing (PSK)
(Gerdes et al., 1986).
1.3

Bacteriophage P1
Bacteriophage P1 is a temperate virus of E. coli that was first discovered in 1951

and gained popularity as a tool in transduction in the years following its discovery
(Bertani, 1951; Cohen et al., 1996; Bertani, 2004). The P1 prophage is transmitted to
E. coli as a virion through horizontal gene transfer (HGT) (Lobocka et al., 2004).
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X
Figure 1.1:Toxin-antitoxin (TA) addiction module
TA plasmids (green circles) are passed to daughter cells (ovals) through vertical gene
transfer, or reproduction. However, offspring that fail to inherit the plasmid still inherit
activated toxin and antitoxin. As the antitoxin levels drop due to degradation, toxin
levels raise, leading to post-segregational killing (PSK). PSK prevents the proliferation
of plasmid-free cells, which increases plasmid stability among the bacterial population.
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HGT refers to the transfer of genes between in a manner other than reproduction, or
vertical gene transfer (Ambile-Cuevas and Chicurel, 1993). The P1 virion is composed
of an icosahedral head attached to a tail. The tail consists of a tube, a contractile sheath,
and six protruding tail fibers. Each tail fiber contains a variable region that determines
the adsorption of P1 on different hosts (Lobocka, et al., 2004).
The P1 prophage exists in two distinct states: the lytic state and the lysogenic state
(Cohen et al., 1996). The lytic state of the P1 prophage involves genes that are
responsible for phage formation, replication, and release (Lobocka et al., 2004). During
the lytic state, large numbers of infective particles of P1 are produced that contain
circularly permuted DNA molecules of approximately 100 kb with a terminal redundancy
(Cohen et al., 1996; Lobocka et al., 2004). The lytic state is divided into an early state
and a late state. In the early lytic state, replication occurs and circular monomeric DNA
molecules accumulate. The late lytic state is marked by rolling circle replication and the
formation of concatemeric DNA (Cohen et al., 1996).
In the lysogenic state, the prophage lysogenizes bacteria as a circular
low-copy-number plasmid that is approximately 90 kb in size
(Cohen et al., 1996; Lobocka et al., 2004). Lysogenesis refers to the stable integration of
a bacteriophage genome into a bacterial strain (Bertani, 1951). Despite the low copy
number - one or two copies per bacterial chromosome – the plasmid is stably maintained,
and the failure to replicate is very rare due to a rigidly controlled replicon and an active
partition site (Chattoraj et al, 1985; Martin et al., 1987; Gazit and Sauer, 1999a). P1
genes expressed in the lysogenic state are involved in plasmid maintenance and in the
inhibition of lytic development (Lobocka et al., 2004).
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1.4

Bacteriophage P1 Operon
The TA operon of bacteriophage P1 is a plasmid addiction system that serves to

stabilize the plasmid in the bacterial cells by selectively killing plasmid-free, or cured,
segregants (Lehnherr et al., 1993). The P1 prophage is organized into an operon with the
labile antitoxin gene preceding the stable toxin gene as seen in Figure 1.2
(McKinley and Magnuson, 2005). These genes are coexpressed and encode two small
proteins, a 73 amino acid antitoxin, Phd, which prevents host death in the presence of the
plasmid, and a 126 amino acid toxin, Doc, which causes death on curing upon loss of the
plasmid prophage (McKinley and Magnuson, 2005; Lehnherr et al., 1993). In cells that
retain the P1 plasmid, transcription of the operon is repressed by the expression of Phd,
which binds to the promoter site through the interaction of its DNA binding domain on
the N-terminal region of the protein, and is further repressed by the coexpression of Doc
(Magnuson et al., 1996; Magnuson and Yarmolinsky, 1998). This negative
autoregulation of the operon by the gene products creates a homeostatic level of Phd and
Doc (Magnuson et al., 1996). In daughter cells that have been rendered plasmid-free, or
cured, active Phd (labile antitoxin) and Doc (stable toxin) proteins are inherited without
the operon (McKinley and Magnuson, 2005). As a result, Phd is degraded and is not
replenished by new protein synthesis, and as the Phd levels are depleted, Doc is freed and
causes cell growth arrest, which eventually leads to cell death as seen in Figure 1.2
(Lehnherr and Yarmolinsky, 1995; McKinley and Magnuson, 2005).
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Figure: 1.2 Model of the P1 plasmid addition operon
The P1 prophage carries a TA system composed of two genes, phd and doc, that encode
an unstable antitoxin followed by a stable toxin. Phd is the unstable antitoxin that
prevents host death, and Doc is the stable toxin, which causes death on curing upon loss
of the plasmid prophage. The P1 addiction operon is autoregulated by the gene products,
creating a steady-state equilibrium of antitoxin and toxin. When present in the cell, Phd
binds and neutralizes Doc, but the unstable antitoxin is degraded by host encoded ClpXP
protease. Therefore, Phd levels must be replenished by new antitoxin expression.
However, upon plasmid loss, expression of Phd and Doc ceases, and the continuing
degradation of Phd causes the antitoxin concentration to drop within the cell. This results
in the release of Doc, which leads to rapid growth arrest and eventually cell death.
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1.4.2

Doc Protein
Doc reversibly induces rapid cell growth arrest by inhibiting translation without

affecting replication or transcription (Garcia-Pino et al., 2008). This eventually leads to
cell death in cured cells (Lehnherr et al., 1993). The structure of Doc, seen in Figure 1.3,
shows a single helical fold consisting of six alpha (α) helices. The central α helices, α3
and α4, are composed mainly of aliphatic side chains, which facilitate the packing of α1
and α2 on one side and α5 and α6 on the other. The helix α4 regulates the binding of
intramolecular inhibitory elements and regulatory proteins. The protein structure also
shows a highly conserved sequence motif among Doc family members,
HXFX(D/E)(A/G)N(K/G), located on loop α3-α4. This loop is referred to as the active
site loop. It contains a patch of conserved surface residues that further incorporates
residues from the loop α1-α2 and the His-13 residue, which serves as the anchor for this
conserved central motif (Garcia-Pino et al., 2008).
Two residues within this conserved active site, His-66 and Asp-70, are essential to
Doc’s toxicity (Magnuson and Yarmolinsky, 1998). Certain mutations of the residues
result in a loss of toxicity. Specifically, the replacement of the Histidine reside at position
66 with tyrosine or arginine results in non-toxic mutants, such as DocH66Y and
DocH66R, respectively. These non-toxic mutants adopt the same conformational fold as
Doc and interact with Phd in a similar manner to induce co-repression of the operon
(Magnuson and Yarmolinsky, 1998; Balasubramanian, 2010).
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Figure 1.3: Crystal structure of Doc of bacteriophage P1
Doc targets protien synthesis and inhibits growth arrest in cells where free toxin levels
have accumulated. The structure of Doc shows an all α helical fold consisting of six α
helices. The strucure shows that two α helices (α1 and α2) are packed on one side of the
central α helcies (α3 and α4) and that the remaining two α helices (α5 and α6) are packed
on the other side. The protein also contains a conserved sequence motif that is
responsible for catalytic activity. This catalytic loop is conserved among Doc homologs.
[PDB: 3KH2AO] (Arbing et al., 2010).
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1.4.3

Phd Protein
Phd has two functions: transcriptional repression of the operon and suppression of

the toxin. The N-terminal region of the protein binds DNA and is responsible for operon
repression, while the C-terminal region binds the toxin and is responsible for toxin
suppression (Smith and Magnuson, 2004; McKinley and Magnuson, 2005). Phd is
proteolytically unstable and degraded by ClpXP, a host-encoded serine protease, but in a
steady-state equilibrium, the antitoxin is continuously replenished and prevents host
death by neutralizing the toxin (Lehnherr and Yarmolinsky, 1995). The native structure
of Phd shows low thermodynamic stability and is largely denatured at 37oC. However,
when bound to operator DNA, Phd adopts a predominately α helical fold, which
stabilizes the native structure (Gazit and Sauer, 1999b). The structure of Phd also shows
an intrinsically disordered C-terminal segment that harbors the toxin interaction sites
(Garcia-Pino et al., 2010). This region of Phd on its own is sufficient for toxin
suppression (Smith and Magnuson, 2004). A crystal structure of the Phd monomer can
be seen in Figure 1.4.
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Figure 1.4: Crystal structure of the bacteriophage P1 Phd monomer
Phd is a bifunctional protein that autoregulates the operon at the level of transcription and
nuetralizes Doc. Phd is unstable and is degraded by host encoded ClpXP. The native
structure of Phd is thermodynamically unstable and is largely denatured at 37oC, but the
protein is stabilized by to DNA or Doc. When bound to Doc, the C-terminal region of
Phd adopts a kinked α helical conformation that divides the C-terminal into a
hydrophobic region and a positively charged region. The positively charged residues
interact with the negatively charged residues of Doc, resulting in complex formation.
[PDB: 3KH2EO] (Arbing et al., 2010).
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1.4.4

Phd-Doc Binding and Interaction
Phd interacts with Doc through two distant binding sites within its C-terminal

domain, resulting in the formation of a complex that bridges two Phd dimers and buries
approximately 25% of the toxin (Garcia-Pino et al., 2010). This heterotrimeric complex
composed of two Phd molecules and one Doc molecule effectively neutralizes the toxin
(Gazit and Sauer, 1999b). A crystal structure of Phd and Doc in complex can be seen in
Figure 1.5. As previously stated, native Phd is thermodynamically unstable; however,
interactions with Doc stabilize the antitoxin, suggesting that Doc binding may help
protect Phd from degradation. Doc binding incudes a change in the antitoxin’s secondary
structure (Gazit and Sauer, 1999b). Specifically, the C-terminal region (residues 52-73)
of Phd adopts a kinked α-helical conformation (Arbing et al., 2010). This kink divides
residues 52-73 into two distinct segments: a hydrophobic region (residues 54-62) and a
negatively charged region (residues 64-73) (Garcia-Pino et al., 2008). The hydrophobic
residues (52-62) are packed into a hydrophobic cavity on the surface of Doc, allowing the
interaction between the negatively charged residues (64-73) of the antitoxin and the
positively charged residues of the toxin (Arbing et al., 2010). This creates a favorable
interaction between the residues in the Phd-Doc binding groove
(Garcia-Pino et al., 2008). However, the two residues essential to Doc’s toxicity, His-66
and Asp-70, are not positioned in the Phd-binding site, and are therefore not impeded by
Phd binding

(Garcia-Pino et al., 2008 and Arbing et al., 2010). This suggests that Phd

sequesters Doc by creating steric hindrance between the toxin and its target or by
inducing a conformational change in Doc (Garcia-Pino et al., 2008).
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Figure 1.5: A crystal structure of Phd and Doc in complex
This complex shows two Phd molecules (beige and white) interacting with two Doc
molecules (red and teal). This interaction takes place at two distant binding sites within
the C-terminal region of Phd, resulting in the stabilization of this intrinsically unfolded
region. After complex formation, the toxin is effectively sequestered by conformational
changes induced by Phd binding or by steric hindrance due to the presence of the bound
antitoxin [PDB: 3KH2] (Arbing et al., 2010).
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1.5

The Mechanism of Doc Inhibition
The accumulation of the toxin in cells that have lost the P1 plasmid results in

Doc-mediated cell death (McKinley and Magnuson, 2005). The toxin targets protein
synthesis, or translation, causing the cell to undergo rapid growth arrest, and without the
antitoxin to counteract the deleterious effects of the toxin, the cell dies
(Garcia-Pino et al., 2008; McKinley and Magnuson, 2005). Early theories suggested that
the toxin binds and inhibits the 30S ribosomal subunit in a manner similar to the
antibiotic hygromycin B, which stalls the progression of translation by stabilizing the
polyribosome, or polysome (Lui et al., 2008). However, recent evidence has shown
catalytic activity in distant homologs of Doc. Therefore, recent theories suggest that Doc
may catalyze an AMPylation, phosphocholination, or phosphorylation event
(Yarbrough et al., 2009; Mukherjee et al., 2011; Castro-Roa et al., 2013).
1.6

Doc Homologs
Doc-related proteins belong to the Fido (Fic/Doc) superfamily of proteins

(Anantharaman and Aravind, 2003; Finn et al., 2010). These two families were merged
based on similarities in their catalytic active sites and their structural organization
(Kinch et al., 2009). The Fido superfamily has been classified into three subfamilies
based on structure (Garcia-Pino et al., 2014). Subfamily I consists of Doc of
bacteriophage P1, which contains an all α-helical structure, while subfamily II includes
the human Huntingtin yeast-interacting protein E (HYPE) that contains a transmembrane
helix and several tetratricopeptide (TPR) repeats. The third subfamily is comprised of the
E. coli Fic protein and its orthologs from diverse bacteria. These proteins contain N- and
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C-terminal insertions as well as insertions between the α1 and α2 helices
(Anantharaman and Aravind, 2003).
Fic (filamentation induced by cyclic AMP) proteins share little sequence
similarity; however, they contain a conserved Fic-domain (Garcia-Pino et al., 2014).
This domain, which is widespread and found in all areas of life, is defined by a conserved
structural fold and a conserved sequence motif that is essential for catalytic activity
(Finn et al., 2010; Worby et al., 2009). This sequence motif consists of nine conserved
residues HXFX(D/E)(A/G)N(G/K)R (Worby et al., 2009).
The structure of the Fic-domain is characterized by a central core of eight
α helices. These eight α helices are arranged in an up and down bundle of six α helices
(α1-α5 and α’) with the other two α helices (α6 and α7) lying perpendicular to the bundle
(Kinch et al., 2009). The fold also contains a β-hairpin inserted between α helices 2 and
3 that connects α helices 4 and 5. This positions the hairpin near the conserved
active-site loop (Kinch et al., 2009; Palanivelu et al., 2011). This catalytic loop is
supported by two α helices and the side chains of the conserved Phe and Asn residues
within the loop. The Phe side chain anchors the active site loop to the hydrophobic core
of the domain, while the Asn residue provides structural support by forming hydrogen
bonds with the peptide backbone. The active site also contains a conserved (A/G)NG
submotif that is thought to create favorable interactions with the phosphate groups within
nucleotide triphosphates (Garica-Pino et al., 2014). A figure of the Fic-domain can be
seen in Figure 1.6.
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Figure 1.6: Crystal structure of the Fic-domain from Helicobacter pylori
The Fic-domain is found in all areas of life including humans. The structure of the Ficdomain shows eight α helices (pink) and a β hairpin (yellow). The Fic-domain also
contains a highly conserved sequence motif important for catalytic activity. [PDB: 2F6S]
(Cuff, et al.).
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1.6.1

AMPylation (Adenylylation)
Certain members of the Fic/Doc superfamily, VopS and IbpA, have been shown

to catalyze the adenylylation, or AMPylation, of target proteins. VopS is an effector
protein produced by Vibrio parahaemolyticus, and IbpA is a surface antigen from
Histophilus somni. These bacterial Fic-domain containing proteins have been shown to
AMPylate host Rho-family GTPases (Yarbrough et al., 2009; Worby et al., 2009). Rho
GTPases are molecular switches involved in signal transduction and regulation of cellular
processes in host cells, including cytoskeleton rearrangement and vesicular trafficking
(Woolery et al., 2010; Hall et al., 2012). GTPases are proteins that bind and hydrolyze
GTP, or guanine triphosphate (Kaibuchi et al., 1999). After binding GTP, the protein
undergoes a conformational change that subsequently stimulates an interaction with a
target protein to yield a cellular response (Hall et al., 2012). It is possible that because
Doc contains a Fic-domain that it catalyzes the AMPylation of a protein substrate
(Cruz et al., 2014).
AMPylation, outlined in Figure 1.7, is a process that involves the reversible
transfer of an adenosine monophosphate (AMP) group to the hydroxyl side chain of a
target protein (Itzen et al., 2011). In this process, the bond between the α and the β
phosphate groups on the adenosine triphosphate (ATP) molecule is cleaved, producing an
AMP group and a pyrophosphate (PPi). The AMP group is then transferred to the
nucleophilic hydroxyl group of a threonine, a tyrosine, or likely a serine residue within a
target molecule. This reaction has been shown to involve the threonine and tyrosine
residues, but the involvement of the serine residue has yet to be seen. However, because
it contains a hydroxyl group, it is likely that this reaction could involve a serine residue
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(Yarbrough and Orth, 2009). After the covalent addition of the AMP to a target, the
activity of the molecule is modified (Woolery et al., 2010). Therefore, the modification
of Rho GTPases through AMPylation by VopS and IbpA result in their inability to
interact with their downstream target proteins. This can lead to the collapse of the host
cell cytoskeleton, cell detachment, and death (Yarbrough et al., 2009; Worby et al.,
2009).
The only human protein containing a Fic-domain, HYPE, showed AMPylation
activity towards Rho GTPases in vitro, suggesting that AMPylation is a universal
post-translational event (Worby et al., 2009; Yarbrough and Orth, 2009). AMPylation
was first discovered, in 1960 by Earl Stadtman in bacterial glutamine synthetase, as a
stable post-translational modification (Stadtman, 2001). This type of modification
involves the formation of stable phosphodiester bonds during protein regulation.
However, AMPylation is also involved in transient reactions that involve the formation of
unstable carboxylate-phosphate anhydrides or phosphodiester bonds (Itzen, 2011).
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Figure 1.7: The AMPylation reaction
In this reaction, the bond between the α and β phosphate group of adenosine triphosphate
(ATP) is cleaved, generating adenosine monophosphate (AMP) and pyrophosphate (PPi).
The resulting AMP group is then transferred to the hydroxyl group of a threonine,
tyrosine, and likely a serine residue within a target molecule. This figure was drawn
using ChemDoodle Chemical Drawing Software.
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1.6.2

Phosphocholination
AnkX of Legionella pneumophila is another example of a bacterial protein that

contains a Fic-domain. Legionella pneumophila is a facultative intracellular pathogen
that injects effector proteins into host cells (Mukherjee et al., 2011). Several of these
proteins interfere with normal vesicular transport processes within the host cell by
modifying Rab and Arf family GTPases through non-covalent and covalent reactions
(Goody et al., 2012). The covalent reactions described so far involve the modification of
the switch II region of Rab1, an important regulatory GTPase of Legionella vesicular
transport (Goody et al., 2012; Muller et al., 2014). DrrA/SidM is a Legionella effector
protein that functions as an AMPylator. It transfers an AMP group to the hydroxyl side
chain of Try77 and Try80 within the switch II region of Rab1b and Rab1a, respectively
(Muller et al., 2010). DrrA and glutamine synthetase adenylyl transferase, the first
AMPylator discovered, share a similar structure as well as the catalytic motif GX11DXD,
which explains their similar catalytic activity (Mukherjee et al., 2011). The second
covalent modification of Rab1 involves AnkX, a Legionella effector protein
(Goody et al., 2012).
Unlike other Fic-domain containing AMPylators, VopS and IbpA, AnkX was
shown to modify Rab1 by attaching a phosphocholine group through a process referred to
as phosphocholination, seen in Figure 1.8 (Mukherjee et al., 2011). This reaction
involves the cleavage of phosphocholine from CDP-choline, producing a cytidine
monophosphate (CMP) group, and the subsequent transfer of the phosphocholine to the
hydroxyl side chain of a threonine, tyrosine, or serine residue within a target molecule
(Goody et al., 2012; Muller et al., 2014). The transfer of the phosphocholine to Ser79 of
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Rab1b by AnkX is mediated by the conserved His residue within the Fic motif and results
in the altered activity of Rab1 (Mukherjee et al., 2011). Modified Rab1 is unable to bind
to GDI (guanine nucleotide dissociation inhibitor) and becomes trapped at the host cell
membrane, impeding vesicular transport (Muller et al., 2014). Therefore,
phosphocholination represents a Fic-domain mediated mechanism that alters host cell
processes (Mukherjee et al., 2011). In addition, the presence of a Fic-domain containing
protein with a different catalytic activity suggests that Doc might catalyze an event other
than the conserved AMPylation reaction (Cruz et al., 2014).

Figure 1.8: The phosphocholination reaction
Phosphocholination involves the cleavage of phosphocholine from CDP-choline,
generating a cytidine monophosphate (CMP) group in the process. After the cleavage of
the diphosphate bond, the phosphocholine group is transferred to the hydroxyl side chain
of a serine, threonine, or tyrosine residue within the target molecule. This figure was
drawn using ChemDoodle Chemical Drawing Software.
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1.6.3

Differences between Doc and Other Proteins Containing a Fic-Domain
Additionally, Doc shows some structural differences compared to the structure of

the Fic domain. Although Doc contains a Fic-domain similar to the topology of other
Fic-domains, it is described as an incomplete Fic fold. The conserved Fic core adopts an
α helical conformation containing eight α helices, whereas the structure of Doc consists
of only six α helices (Garcia-Pino et al., 2008). In addition to lacking the first and the
permuted α helices, Doc also lacks the β-hairpin (Kinch et al., 2009). For these reasons,
the structure of Doc is referred to as the minimal Fic-domain (Garcia-Pino et al., 2008).
However, because Doc interacts with Phd in a 2:1 ratio, interactions between Doc and
Phd are thought to result in a complete core Fic fold. For instance, in the heterotrimeric
complex, Phd replaces the two missing core α helices, thereby complementing the fold
(Garcia-Pino et al., 2008).
As previously stated, the structures of VopS and IbpA contain a complete
Fic-domain containing the β-hairpin as well as the core sequence motif responsible for
AMPylation activity (Yarbrough et al., 2009; Worby et al., 2009). Instead of a separate
antitoxin protein, these proteins contain an inhibitory domain that obstructs ATP-binding
(Engel et al., 2012). It has been proposed that the β-hairpin in these proteins mediates
substrate recognition (Luong et al., 2010; Xiao et al., 2010). Further evidence suggests
that the conserved arginine and histidine residues within the catalytic active site of the
Fic-domain help mediate the enzymatic reaction. The arginine residue is thought to
facilitate proper nucleotide binding, while the histidine residue is thought to create
favorable interactions between the hydroxyl group of the target and the phosphate moiety
of the nucleotide (Xiao et al., 2010; Engel et al., 2012). Because the active-site motif is
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conserved, it is thought that the Fic-domain executes a common catalytic function;
however, differences in the structural elements among Fic proteins may be responsible
for deviations in substrate interaction (Xiao et al., 2010). The lack of the structural Fic
elements in its structure suggest that Doc may catalyze an enzymatic reaction other than
those previously discussed (Goepfert, et al., 2013). Additionally, the chemistry of these
reactions seem to be highly conserved in that they involve nucleotide substrates and the
cleavage of high-energy phosphate bonds (Garcia-Pino et al., 2014). Therefore, Doc may
possess phosphorylation activity (Castro-Roa et al., 2013; Cruz et al., 2014).
1.6.4

Phosphorylation
Phosphorylation, shown in Figure 1.9, is the process of transferring a γ phosphate

group from ATP to the hydroxyl side chain of an amino acid residue within the target
protein (Yarbrough and Orth, 2009). During the cleavage of the γ phosphate from ATP,
adenosine diphosphate (ADP) is produced, which can be used in downstream reactions to
regenerate ATP by the addition of a phosphate group
(Hirschbein et al., 1982; Yarbrough and Orth, 2009). This reaction is catalyzed by
enzymes referred to as kinases (Yarbrough Orth, 2009).
As previously stated, Doc has an incomplete Fic structure, suggesting that Doc
may have adopted a different catalytic function (Goepfert et al., 2013). In fact in recent
studies, Doc has been shown to function as a kinase that phosphorylates the elongation
factor Tu (EF-Tu) (Castro-Roa et al., 2013; Cruz et al., 2014). EF-Tu is a GTPase protein
involved in translation, specifically in the selection and transfer of tRNAs during the
elongation of the peptide chain (Cruz et al., 2014). Post translational modifications of
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this protein lead to its inactivation and the inhibition of translation elongation, resulting in
cell death (Castro-Roa et al., 2013; Cruz et al., 2014).

Figure 1.9: The phosphorylation reaction
The reaction is catalyzed by enzymes referred to as kinases and involves the cleavage of
the of the γ phosphate group from the ATP molecule, generating an adenosine
diphosphate group (ADP). The γ phosphate is then transferred to the hydroxyl side chain
of a serine, threonine, or tyrosine residue within in the target protein. This figure was
drawn using ChemDoodle Chemical Drawing Software.

24

1.7

Objectives
At the beginning of this research, it was well known that Doc inhibits translation,

but the exact mechanism of Doc-induced cell death and the cellular target of the toxin
were unknown. Therefore, the objectives of this research were to develop assays to
confirm that Doc inhibits translation, to determine the mechanism utilized by the toxin,
and to determine the cellular target of the toxin. However, during the course of this
research, two articles were published that involved the same objectives, which were to
determine the mechanism and target of the toxin. Both of these studies confirmed the
results presented in this research.
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CHAPTER TWO

MATERIALS AND METHODS

2.1

Media
Cells were grown on Luria-Bertani (LB) agar or in LB broth (Fisher Scientific)

containing 100 µg/mL of ampicillin (Amp) (Fisher Scientific) or 30 µg/mL of kanamycin
(Kan) (Sigma Chemical) to maintain plasmid selection.
2.2

Strains
All strains were derivatives of E. coli MC1061, except the XY strains, which were

derivatives of E. coli BL21 (Casadaban and Cohen, 1980; Weiner et al., 1994). The
strains are described in Table 2.1, and Table 2.2 describes the phages that were used in
the construction of some of these strains. Bacterial strains were streaked onto LB agar
plates containing the appropriate antibiotics and incubated at 30oC overnight or until
sufficient bacterial colony growth was observed. Colonies that were homogenous in size
and color with a smooth, shiny surface were considered healthy, while colonies that were
heterogeneous in size and color or had a rough surface were considered unhealthy.
Liquid cultures were prepared in sterile 18 x 150 mm glass test tubes by
inoculating 5 mL of LB broth containing the appropriate antibiotics with cells selected
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from a single, isolated colony. These cultures were incubated along with media controls
at 30oC for 12-16 hours in a roller drum set at 30 revolutions per minute (rpm). Freezer
stocks were prepared by mixing 750 µL of each overnight culture with 250 µL of 50%
glycerol (Fisher Scientific) in a sterile screw-cap vial and stored at -80oC.

Table 2.1
Strains
Strain

Description and Constructiona

Source

SC01

λRDM11(P-phd(all)-lacZYA into MC1061,
pKK223-3, placIq, Ampr, Kanr

same as BR7045 Lab
Collection

SC02

λRDM12(Pr92::lacZYA) into MC1061,
pRDM032(Ptac-phd-doc), placIq, Ampr, Kanr

same as BR7029
(Magnuson et al., 1996)

SC03

λRDM11(P-phd(all)-lacZYA into MC1061,
pRDM037(Ptacdoc), placIq, Ampr, Kanr

same as BR7046
(Magnuson and
Yarmolinsky, 1998)

SC04

λRDM11(P-phd(all)-lacZYA into MC1061,
pRDM065(PtacdocH66R), placIq, Ampr, Kanr

same as BR7042
(Magnuson and
Yarmolinsky, 1998)

SC05

λRDM12(Pr92::lacZYA) into MC1061,
pRDM032(Ptac-phd), placIq, Ampr, Kanr

same as BR7040
(Magnuson et al., 1996)

SC06

pBESTluc(Ptacluc) into MC1061, Ampr

This Study

SC07

araD139, Δ(ara-leu)7696, ΔlacX74, galUgalK,
hsdR2(rk - mk +) mcrB1, rpsL (StrR)

same as MC1061
(Casadaban and Cohen,
1980)

XY217

placIq into BL21, Kanr

Zhao, personal
communication

XY223

pX248(Ptacphd-doc-His*) into XY217, placIq,
Ampr, Kanr

Zhao, personal
communication

BL21

E. coli B F- dcm opm T hsdS(rb- mb-) gal

(Weiner et al., 1994)

a. Ampr, Kanr indicate resistance to ampicillin and kanamycin, respectively.
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Table 2.2
Phages
Phage

Description

Source

λRDM11

Pr92 fused to the full coding sequence of Phd
followed by lacZYA into λRS45

(Magnuson and
Yarmolinsky, 1998)

λRDM12

Pr92 transcriptionally fused to lacZYA in
λRS45

(Magnuson et al.,
1996)

2.3

Transformation
This process began by preparing competent cells from strain BR6545. The

bacteria were streaked onto LB agar plates and incubated at 30oC until sufficient colony
growth was observed. Then, an isolated colony was selected and re-streaked onto a new
LB agar plate, which was incubated at 30oC until sufficient bacterial growth was
obtained. After the second streak, overnight cultures were prepared by inoculating an
isolated colony in 5 mL of LB broth and incubating the cultures at 30oC in a roller drum
along with a media control for 12-16 hours. Next, 100 µL of each overnight culture were
incubated in 5 mL of LB broth for 3 hours to allow the cells to reach the mid log phase.
After the 3-hour growth period, the cultures were pelleted in a Damon IEC Division
HN-S centrifuge at approximately 3,675 rpm or relative centrifugal force (RCF) of
1926 x g for 5 minutes. The pellet was resuspended in 1 mL of ice cold 100 mM CaCl2
and incubated on ice for 20 minutes. The solution was then transferred to a clean 1.5 mL
microcentrifuge tube and centrifuged at 13,000 rpm for 5 minutes. After removing the
supernatant, the resulting pellet was resuspended in 500 µL of ice cold 100 mM CaCl2.
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The second part of this process involved the transformation of the pBEST luc
vector (Promega) into the competent cells. Therefore, 1 µL of pBEST luc DNA was
added to 50 µL of the competent cells. This solution was incubated on ice for 20 minutes
and then incubated at 42oC for exactly 90 seconds. The cells were incubated on ice for an
additional 2 minutes. Then, 250 µL of LB broth were added to the solution, and it was
incubated for 40 minutes at 30oC. Finally, 100 µL of each sample were spread on LB
agar plates containing ampicillin. The plates were incubated at room temperature to
allow the solution to absorb into the agar, and then they were incubated at 30oC until
sufficient bacterial growth was observed. The samples containing transformants were
considered to be successfully transformed as long as the no-plasmid control plates
showed no bacterial growth. The transformants were colony purified by plating on LB
agar containing ampicillin and incubating at 30oC until sufficient growth was observed.
Cells from an isolated colony were selected and grown overnight in liquid culture, and
then a freezer stock was prepared.
2.4

Plasmid Isolation
Strains containing the plasmids of interest were grown on LB agar plates

containing the appropriate antibiotics. The LB agar plates were incubated at 30oC until
sufficient bacterial growth was observed. A single, isolated colony was selected from
each strain and re-streaked onto a new LB agar plate with the required antibiotics. These
plates were also incubated at 30oC until sufficient bacterial growth was observed. An
overnight culture was prepared by inoculating a single, isolated colony in 5 mL of LB
broth containing the appropriate antibiotics. The cultures were then incubated at 30oC in
a roller drum set at 30 rpm for 12-16 hours. Next, the cultures were centrifuged at room
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temperature for 5 minutes in a Damon IEC Division HN-S centrifuge at approximately
3,675 rpm.
After pelleting the cultures, the plasmids were isolated using the QIAprep
MiniPrep Kit from Qiagen. The pellets were resuspended in 250 µL of Buffer P1. Then
the samples were transferred to a 1.5 mL microcentrifuge tube and 250 µL of Buffer P2
were added to each. The samples were mixed thoroughly by inverting the tubes 4 to 6
times and incubated at room temperature for 5 minutes. Next, 250 µL of Buffer N3 was
added, and the tubes were inverted 4 to 6 times to mix. The samples were immediately
centrifuged for 10 minutes at 13,000 rpm. The lysate was transferred from the samples to
a QIAprep Spin Column in a collection tube. After centrifuging for 1 minute at 13,000
rpm and discarding the flow through, 750 µL of Buffer PE containing ethanol were added
to each Spin Column. The columns were centrifuged for 1 minute at 13,000 rpm. The
flow-through was discarded, and the columns were centrifuged for an additional minute
at 13,000 rpm to remove any excess buffer. The Spin Columns were then transferred to
clean microcentrifuge tubes. Next, 50 µL of Buffer EB were added to the Spin Column to
elute the DNA. The samples were centrifuged at 13,000 rpm for 1 minute, the Spin
Columns were discarded, and the eluted DNA was stored at -20oC. The concentration of
the eluted DNA was measured with a ThermoScientific Nano Drop 2000. Plasmid
descriptions are presented in Table 2.3.
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Table 2.3
Plasmids
Plasmid

Description

Vector

pKK223-3

Ptac

Ptac expression
vector, pMB1 ori,
Ampr

pRDM032

Ptacphd-doc

pKK223-3, Ampr

Phd and Doc

(Magnuson et al.,
1996)

pRDM037

Ptacdoc

pKK223-3, Ampr

Doc

(Magnuson and
Yarmolinsky, 1998)

DocH66R

(Magnuson and
Yarmolinsky, 1998)

pRDM065

Insert DNA

PtacdocH66R pKK223-3, Ampr

Source
(Brosius and Holy,
1984)

pRDM034

Ptacphd

pKK223-3, Ampr

Phd

(Magnuson et al.,
1996)

pBEST luc

Ptacluc

Ptacluc

Luciferase

Promega
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2.5

Protein Purification

2.5.1

Cell Preparation
The strain expressing Phd and His6-tagged Doc was grown on LB agar plates

containing the appropriate antibiotics. The plates were incubated at 30oC until sufficient
growth was observed. Then the cells were colony purified by re-streaking a single, wellisolated colony onto a new LB agar plate containing the appropriate antibiotics and
incubating at 30oC until sufficient growth was observed. Next, 5 mL of LB broth
containing the appropriate antibiotics were inoculated with an isolated colony. This
liquid culture was then incubated at 30oC for 12-16 in a roller drum set at 30 rpm. The
optical density of each overnight culture was measured at 600 nm (OD600), and 1 L of LB
broth containing the appropriate antibiotics was inoculated with 1 mL of overnight
culture at 0.5 absorbance units (AU). Next, the cultures were grown in a shaker water
bath at 30oC at 150 rpm. The flasks were incubated while shaking until the OD measured
0.5, and then 1 mL of isopropyl-β-D-thiogalactopyranoside (IPTG) was added to induce
protein expression. The samples then were incubated with shaking for an additional 6
hours. Next, the final OD600 was measured and the cells were pelleted at 8,000 rpm for
15 minutes at 4oC. After discarding the supernatant, the pellets were stored at -20oC.
2.5.2

Sample Preparation
The prepared pellet was thawed on ice and resuspended in a 4.5 mL solution

containing 1.42 M ammonium sulfate, 1 µL of 25 U/µL benzonase, 100 µL of
100 mg/mL PMSF in 100% ethanol, and 10 µL of 10 mg/mL lysozyme. After dissolving
the pellet, the solution was separated into 1 mL aliquots in 1.5 mL microcentrifuge tubes.
These aliquots were then sonicated on ice in a 95% ethanol bath until the suspension was
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visibly clear. Next, the sonicated samples were centrifuged at 4oC for 30 minutes at
16,000 rpm. The supernatants were then transferred to a 15 mL Falcon tube, and the
precipitate was discarded. Then, half a volume of 4 M ammonium sulfate was added the
solution. Next, the sample was incubated overnight at 4oC on ice, and then the overnight
sample was centrifuged at 4oC in a Damon IEC Division HN-S centrifuge at
approximately 3,675 rpm for 30 minutes. After this centrifugation, the supernatant was
discarded and the pellet was resuspended in 5 mL of purification buffer AA and kept on
ice while the column was prepared. Refer to Table 2.4 and 2.5 for buffer composition
and preparation.
2.5.3

Column Preparation and Affinity Chromatography

The 1 mL Ni-NTA HiTrap Chelating Column (Pharmacia) was attached to the BioRad
Econo System Pump, and the column was calibrated to a flow rate of 1 mL/minute.
Next, the column was washed consecutively with 5 mL of filtered diH2O, 5 mL of
0.5 M NaOH, 5 mL of filtered diH2O, 5 mL of 0.05 M EDTA, 5 mL of diH2O, and
0.1 M NiSO4. After purging and washing the column lines with Buffers AA and BB, the
protein sample was loaded onto the column, and the BioRad Econo system pump was
programmed as seen in Table 2.6. Elution fractions from the column were then collected
in 1 mL aliquots by a BioRad Econo system fraction collector. Next, the collected
elution fractions were pooled into 5 mL samples based on their absorbance at 280 nm and
precipitated overnight at 4oC by adding 0.4 g/L of dry ammonium sulfate. These
overnight samples were then centrifuged at approximately 3,675 rpm for 30 minutes at
4oC in a Damon IEC Division HN-S centrifuge. After discarding the supernatants, the
pellets were resuspended in 500 µL of resuspension buffer.
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Table 2.4
Buffer Composition
Guanidine HCl Imidazole

NaN3

Buffer

Tris pH 8.0

NaCl

AA

50 mM

300 mM

2M

20 mM

-

BB

50 mM

300 mM

3.5 M

20 mM

-

CC

50 mM

300 mM

-

20 mM

-

DD

50 mM

300 mM

-

250 mM

-

Resuspension

50 mM

250 mM

-

-

0.02%

Table 2.5
Buffer Preparation
Buffer

Tris
pH 8.0

NaCl

Guanidine
HCl

Imidazole

NaN3

diH2O

AA

2.5 mL

3 mL

16.7 mL

1 mL

-

26.8 mL

BB

2.5 mL

3 mL

29.2 mL

1 mL

-

14.3 mL

CC

2.5 mL

3 mL

-

1 mL

-

43.5 mL

DD

2.5 mL

3 mL

-

12.5 mL

-

32 mL

Resuspension

0.3 mL

0.3 mL

-

-

0.6 mL

4.8 mL
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Table 2.6
Column Program
Buffer

mL

%-%

Function of Step

AA

20

100-100

Binding Buffer

BB

5

0-100

Increasing guanidine HCl gradient – to denature the
proteins and prevent complex formation

BB

5

100-100

Isocratic Flow

BB

5

100-0

Decreasing guanidine HCl gradient

AA

5

100-100

Wash the column

CC

10

100-100

Remove any remaining guanidine HCl – to facilitate the
refolding of the bound His-Doc

DD

5

100-100

Elute the bound His-Doc

DD

5

100-100

Isocratic flow – removal of any remaining His-Doc

2.5.4

SDS PAGE
To confirm the presence of His6-tagged Doc within the precipitated elution

fractions, 10 µL of each elution fraction and 5 µL of the crude lysate samples (the
starting material, the supernatant, and the pellet sample) were transferred to 1.5 mL
microcentrifuge tubes. Three volumes of ice cold 20% Trichloroacetic acid (TCA) were
added to each tube, and the tubes were incubated at -20oC for 5 minutes. The samples
were then centrifuged for 15 minutes at 13,400 rpm. The supernatant was discarded, and
the pellet was washed with 100% ice cold ethanol. After removing the ethanol, the
samples were allowed to dry for 1 hour. Next, the samples were resuspended in 10 µL of
1X LDS sample buffer (NuPAGE) containing 4% BME. While the samples were
denaturing in a 90oC water bath for 10 minutes, the SDS PAGE apparatus was assembled
and the anode and cathode reservoirs were filled with 1X MES SDS Running Buffer
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(NuPAGE) stored at 4oC. After 10 minutes at 90oC, the samples were centrifuged for 3
minutes at 13,200 rpm. Then 5 µL of each sample and 3 µL of the PageRuler Plus
Pre-stained Protein Ladder (ThermoScientific) were loaded onto the NuPAGE 12%
Bis-Tris precast gel (Novex).
2.5.5

Gel Staining
After the gel was run at 150 volts for approximately 45 minutes, it was removed

from the casting frame and stained with SimplyBlue SafeStain (Invitrogen). The gel was
washed 3 times for 1 minute in 75 mL of diH2O heated in the microwave for
approximately 50 seconds. Then the gel was stained for 5 minutes in 50 mL of SafeStain
(Invitrogen) heated in the microwave for approximately 50 seconds and the gel was
de-stained overnight in room temperature diH2O. The gel was then stained with Silver
Nitrate. The gel was washed in Silver Stain Sensitizer solution containing 0.02% sodium
thiosulfate. Next, it was washed 3 times for 5 minutes in diH2O. Then the gel was
stained in silver nitrate solution containing 0.2% silver nitrate and 0.076% formalin for
20 minutes. After the gel was washed twice in diH2O for 1 minute, it was developed in
Silver Stain Developer solution containing of 6% sodium carbonate, 0.05% formalin, and
0.0004% sodium thiosulfate. Once good band intensity was observed, the developer
solution was removed, and the Silver Stain stop solution containing 50% methanol and
12% glacial acetic acid was added. The gel was washed in the stop solution for 5
minutes. After the staining process was complete, the gel was transferred to a
9.5 X 8.5 cm piece of thick chromatography paper (Fisherbrand) and covered with plastic
wrap. Then it was vacuum dried with an E-C Apparatus Corporation gel dryer and gel
dryer pump at 80oC for 45 minutes.

36

2.5.6

Protein Quantification
The concentration of the purified His6-tagged Doc protein was determined using a

Bradford Assay. In this procedure, a 1 mg/mL BSA solution was created from a
10 mg/mL stock solution. Next, the Bradford Reagent was prepared by dissolving
100mg of Coomassie Brilliant Blue G-250 in 50 mL of 95% ethanol. After adding
100 mL of 85% (w/v) phosphoric acid to the solution, it was diluted to 1L with diH2O.
Before use, the cuvettes were standardized to an absorbance of -/+0.004 at 595 nm,
washed 3 times with 100% ethanol, rinsed 3 times with diH2O, and dried overnight at
room temperature. After filtering the reagent through a 0.45µm sterile filter, 1 mL was
added to each cuvette. Three sets of BSA standards were prepared in the manner outlined
in Table 2.7. The samples were mixed by pipetting, and a standard blank was created by
adding 40 µL of diH2O to 1 mL of Bradford Reagent. Next, one set of unknown samples
was prepared in the manner outlined in Table 2.8, and a buffer control was created by
adding 40 µL of the resuspension buffer to 1 mL of the Bradford Reagent. After gently
mixing the samples, they were incubated at room temperature for 5 minutes. Then the
absorbance of each sample was measured at 595 nm, and the average of the BSA
standards was determined.
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Table 2.7
BSA Standards
BSA (µL)

diH2O (µL)

BSA Concentration (µg/µL)

0

40

0

5

35

0.125

10

30

0.25

15

25

0.375

20

20

0.5

25

15

0.625

30

10

0.75

35

5

0.875

40

0

1

Table 2.8
Unknown Samples
Unknown (µL)

diH2O (µL) Dilution

5

35

0.125

10

30

0.25

20

20

0.5

40

0

1
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2.6

S30 Extract Preparation
The S30 extract, or cell free extract, was prepared using the protocol described in

the JoVE article “Isolation of Translating Ribosomes Containing Peptidyl-tRNAs for
Functional and Structural Analyses” (Shirole et al., 2011). This protocol was adapted
from the method described by Zubay (1973). First, two grams of an E. coli bacterial
pellet were obtained from mid-log phase cultures. This pellet was washed twice by
centrifugation at 5000 RCF for 5 minutes at 4oC with 500 mL of a buffer containing 10
mM Tris-acetate (pH 8.0), 14 mM magnesium acetate, 60 mM potassium acetate, and 50
µg/mL PMSF. The pellet was then resuspended in 40 mL of this buffer. Next, the
bacterial cells were disrupted using a French press applying 600 psi pressure, and the
suspension was collected in a 50 mL clean glass tube. This suspension was then treated
with 1mM DTT and centrifuged at 30,000 RCF for 30 minutes. The resulting supernatant
was centrifuged at 30,000 RCF for 30 minutes. After centrifugation, the final supernatant
was separated into 1 mL microcentrifuge tubes, frozen using a dry ice-ethanol mixture or
liquid nitrogen, and stored at -60oC or -80oC.
This S30 (cell free) extract was mixed with a buffer solution containing 1 mM
each of the 20 amino acids or 19 of the desired amino acids. Amino acids mixtures
lacking a particular amino acid were used to replace that amino acid with a radiolabeled
amino acid. Then the premix, containing 40 mM Tris-acetate (pH 8.0), 10 mM
magnesium acetate, 175 mM potassium acetate, 10 mM ammonium acetate, 2 mM DTT,
2 mM ATP, 0.5 mM GTP, 30 mM PEP, 0.3 U/mL of pyruvate kinase, 3.5% polyethylene
glycol 8000, 1 mM spermidine, 20 µg/mL folinic acid, and 250 µg/mL of E. coli tRNA,
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was added to the reaction mixture. When mixed together, these 3 mixtures facilitate
in vitro transcription and translation.
2.7

Doc Inhibition Assay
The DNA mixtures, containing the plasmids of interest and a master mix,

containing [35S] – Met (PerkinElmer) were prepared. Then, 8.5 µL of the master mix was
added to each 1.5 µL DNA mixture. Refer to Table 2.9 and Table 2.10 for details on the
DNA mixtures and the reaction mixture, respectively. The solutions were mixed well
with the pipette tip and centrifuged at 13,200 rpm for approximately 5 seconds to bring
the reaction mixtures to the bottom of the tubes. The samples were then incubated at
37oC for an hour and a half in a heat block. Following a 5 minute incubation on ice to
stop the reactions, the samples were precipitated with 40 µL of ice cold acetone and
incubated at -20oC for 1 hour. Next, the samples were centrifuged at 13,200 rpm for
15 minutes. The supernatant was removed, and the pellets were dried for 1 hour at room
temperature and resuspended in 10 µL of 1X LDS sample buffer (NuPAGE) with
4% BME. The samples were denatured at 90oC for 10 minutes as the SDS PAGE
apparatus was assembled with a NuPAGE 12% Bis-Tris precast gel (Novex). Both the
anode and cathode reservoirs were filled with 1X MES SDS Running Buffer (NuPAGE)
stored at 4oC. After centrifuging the samples for 3 minutes at 13,200 rpm, 3 µL of the
Page Ruler Plus pre-stained protein ladder (ThermoScientific) and 5 µL of each sample
were loaded onto the gel. The gel was run at 75 volts for 110-130 minutes, removed
from the casting frame, and placed on a 9.5 X 8.5 cm sized piece of thick
chromatography paper (Fisherbrand). Then it was covered with plastic wrap and
vacuumed dried for 45 minutes at 80oC with the E-C Apparatus gel dryer and gel dryer
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pump. Once the gel was dry, it was placed in an autoradiography cassette
(FisherBiotech) with an intensifying screen and exposed to Kodak Biomax XAR high
performance autoradiography film (Sigma-Aldrich) overnight at room temperature. The
film was developed for 1 minute in Kodak Developer and Replenisher for
autoradiography film (Sigma-Aldrich), rinsed in diH2O for 30 seconds, fixed for 1 minute
with Kodak Fixer and Replenisher for autoradiography film (Sigma-Aldrich), and hung at
room temperature to dry.

Table 2.9
DNA mixtures and original plasmid and protein concentrations for the Doc
Inhibition Assay
Plasmid: pBEST luc

Protein: Doc

Original Plasmid Concentration: 0.194 µg/µL

Original Protein Concentration: 0.542 µg/µL

DNA Mixture: 0.8 µL pBEST luc +
0.7 µL diH2O

DNA Mixture: 1.0 µL Doc (0.0375 mM) +
0.8 µL pBEST luc

Table 2.10
Reaction Mixture for the Doc Inhibition Assay
Substrate

Volume (µL)

Amino Acid Mixture - Methionine

1.0

S30 Premix

4.0

S30 Extract

3.0

[35S] – Met

0.5
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2.8

AMPylation Assay
The DNA mixtures and the reaction mixture for this assay are outlined in

Table 2.11 and 2.12, respectively. After the mixtures were prepared, 17 µL of a master
mix containing α[32P] – ATP (PerkinElmer) were added to each 3 µL DNA mixture. The
samples were then mixed with the pipette tip and centrifuged at 13,200 rpm for
approximately 5 seconds to bring the reaction mixture to the bottom of the tubes. Next,
the samples were incubated at 37oC for an hour and a half in a heat block and then placed
on ice for 5 minutes to stop the reactions. Then 160 µL of ice cold acetone and 20 µL of
100% TCA were added to each sample. The samples were incubated at -20oC, and then
centrifuged at 13,200 rpm for 15 minutes. The supernatant was discarded, and the pellet
was washed twice with 100% ethanol. After 20 µL of ice cold 100% ethanol was added
to each sample, the samples were centrifuged at 13,200 rpm for 15 minutes. Then the
ethanol was removed. Once the pellets were washed, they were dried at room
temperature for 1 hour. The pellets were then resuspended in 10 µL of 1X LDS sample
buffer (NuPAGE) containing 4% BME in preparation for SDS gel electrophoresis. The
NuPAGE 12% Bis-Tris precast gel (Novex) was placed onto the assembled
electrophoresis apparatus, and both reservoirs were filled with 1X MES SDS running
buffer (NuPAGE) stored at 4oC. After resuspending the pellets in 10 µL of 1X LDS
sample buffer (NuPAGE) containing 4% BME, the samples were denatured in a 90oC
water bath for 10 minutes, centrifuged for 3 minutes at 13,200 rpm, and then loaded onto
the gel. Specifically, 3 µL of the PageRuler Plus pre-stained protein ladder
(ThermoScientific) and 5 µL of each sample were loaded onto the gel, and the gel was
run at 75 volts for 110-130 minutes.
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Once electrophoresis was complete, the gel was removed from the casting frame
and transferred to a 9.5 X 8.5 cm piece of thick chromatography paper (Fisherbrand),
which was covered with plastic wrap. Then it was vacuum dried, using the E-C
Apparatus gel dryer and gel pump, at 80oC for 45 minutes. After drying, the gel was
exposed to Kodak Biomax XAR high performance autoradiography film (Sigma-Aldrich)
and placed in an autoradiography cassette (FisherBiotech) with an intensifying screen
overnight at room temperature. The film was then developed for 1 minute with Kodak
Developer and Replenisher for autoradiography film (Sigma-Aldrich). Next, it was
rinsed in diH2O for 30 seconds, and then fixed for 1 minute in Kodak Fixer and
Replenisher for autoradiography film (Sigma-Aldrich). Finally, it was hung at room
temperature to dry.

Table 2.11
DNA mixtures and original plasmid concentrations for the AMPylation Assay
and the Phosphorylation Assays
Plasmids

Descriptors

Original Plasmid
Concentration (µg/µL)

Plasmid
Amount (µL)

diH2O
Amount (µL)

pKK223-3

Ptac

0.107

2.8 µL

0.2 µL

pRDM032

Ptacphd-doc

0.279

1.1 µL

1.9 µL

pRDM034
&
pRDM037

Ptacphd

Ptacphd: 0.077

3.8 µL

-

1.5 µL

-

pRDM034

Ptacphd

0.077

3.8 µL

-

pRDM065

PtacdocH66R

0.107

2.8 µL

0.2 µL

pRDM037

Ptacdoc

0.204

1.5 µL

1.5 µL

Ptacdoc

Ptacdoc: 0.204
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Table 2.12
Reaction mixture for the α/γ[32P] – ATP assays
Substrate

2.9

Volume (µL)

DNA mix + diH2O

3

Amino Acid Mixture - Cysteine

1

Amino Acid Mixture - Leucine

1

S30 Premix

8

S30 Extract

6

H2O

0.5

α/γ[32P] – ATP

0.5

Phosphorylation Assay
The phosphorylation assay was performed in a manner similar to the protocol

described in the AMPylation Assay section, except that γ[32P] – ATP was used as the
radiolabel and 3 µL of BLUEstain 3 protein ladder (Gold Biotechnology) was used as the
molecular weight marker. The DNA mixtures and the reaction mixture are outlined in
Tables 2.11 and 2.12, respectively.
2.10

Phosphorylation Specificity Assay
Refer to the AMPylation Assay section for the phosphorylation specificity assay

protocol, to Table 2.13 for the DNA mixtures, and to Table 2.12 for the reaction mixture.
In this experiment, the DNA mixtures were prepared with and without various antibiotics,
including kanamycin (30 mg/mL), spectinomycin (80 mg/mL), chloramphenicol
(20 mg/mL), and erythromycin (10 mg/mL). The antibiotic stock solutions were created
by dissolving the required amount of antibiotic in the appropriate volume of diH2O or
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100% ethanol in a 15 mL Falcon tube. Once the antibiotics were dissolved in solution by
vortexing, the solutions were filtered through a 0.45 µm sterile filter. Then, 1 µL of each
10X solution, prepared from a 1000X stock solution, was added to the appropriate DNA
mixtures. After the DNA mixtures were prepared with the appropriate antibiotics, the
plasmids with and without antibiotics were incubated in the S30 reaction mixture
containing the γ[32P] – ATP radiolabel at 37oC for an hour and a half. The remainder of
the protocol follows the same steps previously discussed in the AMPylation Assay
protocol.

Table 2.13
DNA mixtures and original plasmid concentrations for the Phosphorylation
Specificity Assay
Plasmids

Original
Concentration

DNA Mixture

Antibiotics

pBEST luc

0.194 µg/µL

1.6 µL Ptac luc

1.4 µL diH2O

pBEST luc

0.194 µg/µL

1.6 µL Ptac luc

1.4 µL kanamycin

pBEST luc

0.194 µg/µL

1.6 µL Ptac luc

1.4 µL spectinomycin

pBEST luc

0.194 µg/µL

1.6 µL Ptac luc

1.4 µL chloramphenicol

pBEST luc

0.194 µg/µL

1.6 µL Ptac luc

1.4 µL erythromycin

pRDM037

0.204 µg/µL

1.5 µL Ptacdoc

1.5 µL diH2O
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2.11

Treatment with Degradative Enzymes
This protocol was adapted from the AMPylation Assay protocol previously

described. The DNA mixtures, seen in Table 2.14, and the reaction mixture containing
γ[32P] – ATP, refer to Table 2.13, were prepared, mixed together, and briefly centrifuged
to bring the reaction mixture to the bottom of the tube. The samples were then incubated
at 37oC for 30 minutes. Next, 1 µL of 0.25 U/µL of benzonase (Novagen), 1 µL of
10 mg/mL RNase A (ThermoScientific), and 1 µL of 20 mg/mL of proteinase K
(New England BioLabs) were added to the appropriate samples (refer to Table 2.13).
Then the samples were incubated at 37oC for an additional hour. The remainder of the
protocol is similar to the protocol described in the AMPylation Assay section.

Table 2.14
DNA mixtures and original plasmid concentrations for the Treatment with
Degradative Enzyme experiment
Plasmids

Original
Concentration

DNA Mixture

Spike

pRDM037

0.204 µg/µL

1.5 µL Ptacdoc+ 1.5 µL diH2O

-

pRDM037

0.204 µg/µL

1.5 µL Ptacdoc + 1.5 µL diH2O

1.0 µL DNase

pRDM037

0.204 µg/µL

1.5 µL Ptacdoc + 1.5 µL diH2O

1.0 µL RNase

pRDM037

0.204 µg/µL

1.5 µL Ptacdoc + 1.5 µL diH2O

1.0 µL Proteinase
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CHAPTER THREE

RESULTS AND DISCUSSION

3.1 Protein Purification
The silver stained SDS PAGE gel containing the collected elution fractions and
the crude lysates from the protein purification can be seen in Figure 3.1. The gel showed
that lane 10, which corresponds to elution pool 9, produced a single band at
approximately 14,000 Daltons, which corresponds to the Doc toxin. The concentration of
the isolated protein was determined by a Bradford Assay using the BSA protein to
generate a standard curve of samples with known concentrations. The values obtained
from the Doc samples with unknown concentrations were then fitted to this standard
curve and the concentration of Doc protein was determined to be 0.542 µg/µL.
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Figure 3.1: Ni-NTA affinity chromatography of His6-tagged Doc
The XY223 cells expressing Phd and His6-tagged Doc were grown on LB agar containing
the appropriate antibiotics and culture purified. Then an overnight culture was produced
and protein expression was induced by adding IPTG. The culture pellet was resuspended
in a lysis buffer, and then the solution was sonicated and precipitated with ammonium
sulfate. Next, the Ni-NTA column (Pharmacia) was calibrated, washed with NiSO4, and
equilibrated with buffer. The sample, which was resuspended in the binding buffer
(buffer AA), was loaded onto the column, and the column was programmed in the
manner outlined in Table 2.6. During chromatography, the guanidine HCl gradient was
increased to partially denature the Phd and Doc proteins to prevent complex formation,
and then decreased to allow the refolding of His6-tagged Doc. The refolded His6-tagged
Doc was eluted from the column using imidazole. Then, the presence of His6-tagged Doc
in the collected elution fractions was determined by SDS PAGE. The gel was run at
150 volts for approximately 45 minutes, and then stained with Silver stain. For further
experimental details see Sections 2.5.1 to 2.5.5. Lane 10, which corresponds to elution
pool 9, shows an isolated band at approximately 14 kDa. This corresponds to the
presence of Doc, which is approximately 14 kDa.
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3.2 Doc Inhibits Protein Synthesis
To confirm that Doc inhibits translation, [35S] – Met was used in conjunction with
the S30 extract mixture to label newly translated proteins from the plasmid encoding
luciferase (pBEST luc). The S30 reaction mixture was devoid of methionine amino
acids, which allowed the incorporation of radiolabeled methionine during in vitro
translation. Therefore, the expected results were that the purified Doc toxin would inhibit
the translation of the pBEST luc plasmid and result in a loss of band signal in the samples
containing the toxin. The resulting autoradiogram, seen in Figure 3.2, showed a loss of
band signal in the samples that were co-incubated with the toxin, confirming that Doc
does inhibit translation.
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Figure 3.2: Doc inhibits protein synthesis
In this experiment, the pBEST luc plasmid encoding luciferase (Ptacluc) was incubated
with and without 0.0375 mM of the affinity purified His6-tagged Doc protein in the S30
extract and [35S] – Met was added to the reaction to track the synthesis of newly
translated proteins in vitro. After the reaction mixtures were incubated, they were
precipitated with TCA, denatured, and separated by SDS PAGE. The gel was run at 75
volts for 110-130 minutes, vacuum dried, and then exposed overnight at room
temperature to autoradiography film in an autoradiography cassette with an intensifying
screen. Refer to Section 2.7 for complete details on the Doc inhibition assay. The dark
bands seen in the lanes containing the pBEST luc plasmid (Ptacluc) are newly translated
proteins that have been labeled by the incorporation of [35S] – Met. The lanes containing
the pBEST luc plasmid (Ptacluc) that were co-incubated with the Doc protein show a loss
of band signal. This confirms that Doc inhibits translation.
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3.3 AMPylation Assay
Doc is homologous to the Fic family of proteins, some of which have been shown
to catalyze AMPylation reactions. Therefore, the toxin was tested for AMPylation
activity using α[32P] – ATP. To determine if there was a Doc-dependent AMPylation
event occurring, plasmids encoding a vector control (pKK223-3), Phd and Doc
(pRDM032), Phd (pRDM034), nontoxic Doc (pRDM065), or Doc (pRDM037) were
incubated in the S30 reaction mixture with α[32P] – ATP to track to the transfer of the
α phosphate group during in vitro transcription/translation. The toxin was expected to
catalyze the transfer of the AMP group containing the radiolabeled phosphate from
α[32P] – ATP to a target substrate. In other words, Doc-dependent bands were expected
on the autoradiogram. However, the observed results, seen in Figure 3.3, showed that all
of the samples produced dark bands. The autoradiogram was placed over the gel
containing the protein ladder for a molecular weight reference. The dark background
present in each lane of the autoradiogram was a result of the incorporation of the
radiolabeled α phosphate group into the mRNA chain. The bottom of the autoradiogram
shows a dark mass that was a result of pooled radiolabeled ATP. The results of this
experiment showed that there was not a Doc-dependent AMPylation event occurring.
This suggests that Doc may catalyze an enzymatic event other than AMPylation. As
previously stated, AnkX of Legionella is a Fic-domain containing protein that catalyzes a
phosphocholination reaction instead of the AMPylation reaction seen in VopS and IbpA.
Because Doc does not appear to have the ability to AMPylate, it was tested for
phosphorylation activity as this is a related reaction, which involves the transfer of the
γ phosphate rather than the α phosphate.
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Figure 3.3: AMPylation assay
Plasmids encoding a vector control (pKK223-3), Phd and Doc (pRDM032), Phd
(pRDM034), nontoxic Doc (pRDM065), or Doc (pRDM037) were incubated in the S30
reaction mixture with α[32P] – ATP in order to track the transfer of the α phosphate
group. The reactions were then precipitated with TCA, denatured, and separated by
electrophoresis. SDS PAGE was run at 75 volts for 110-130 minutes, and then gel was
vacuum dried. Next, the gel was exposed to autoradiography film in an autoradiography
cassette with an intensifying screen. After an overnight exposure at room temperature,
the film was developed. See Section 2.8 for the complete AMPylation assay protocol.
The autoradiogram was laid over the gel, which contained pre-stained molecular weight
markers, and then photographed. The dark background in each lane is a result of
α[32P] – ATP incorporation into the mRNA, and the dark mass at the bottom of the film is
due to excess radiolabeled ATP. The autoradiogram showed the same bands in all of the
samples, indicating that there is not a Doc-dependent AMPylation event occurring.
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3.4 Phosphorylation is Doc-dependent
To determine if there was a Doc-dependent phosphorylation reaction occurring,
γ[32P] – ATP was used to track the transfer of the γ phosphate group during in vitro
transcription and translation of the plasmids encoding a vector control (pKK223-3), Phd
and Doc (pRDM032), Phd (pRDM034), nontoxic Doc (pRDM065), or Doc (pRDM037).
If Doc does catalyze a phosphorylation reaction, then the autoradiogram would show a
band that was present only in the Doc sample and not present in any of the other samples.
Figure 3.4 shows a photograph of the phosphorylation assay autoradiogram on top of the
gel containing the pre-stained protein ladder. The autoradiogram showed the presence of
a band between 53-41 kDa that occurs only in the Doc sample. This indicates the
presence of a macromolecule that has been modified by the addition of the radiolabeled γ
phosphate group. The fact that this band appears only in the Doc sample and not in the
sample containing Phd or the non-toxic mutant (DocH66R), confirms that there is a Docdependent phosphorylation event.
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Figure 3.4: Phosphorylation is Doc-dependent
In this experiment, the plasmids encoding a vector control (pKK223-3), Phd and Doc
(pRDM032), Phd (pRDM034), nontoxic Doc (pRDM065), or Doc (pRDM037) were
incubated with γ[32P] – ATP in the S30 extract to track the transfer of the γ phosphate
group in vitro. The samples were then precipitated with TCA, denatured, and separated
by SDS PAGE at 75 volts for 110-130 minutes. The gel was vacuum dried and exposed
to autoradiography film over 3 nights at room temperature in an autoradiography cassette
with an intensifying screen. Refer to Section 2.9 for details about the phosphorylation
assay protocol. The autoradiogram was laid over the gel, which contained the pre-stained
molecular weight markers, and then photographed. The autoradiogram showed the
presence of a band between 53-41 kDa in the Doc lane only. This band corresponds to
the presence of a macromolecule that has been modified by the addition of the
γ phosphate from the radiolabeled ATP. This result confirms that there is a
Doc-dependent phosphorylation event.
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3.5 Phosphorylation is Doc-specific
Though it appears that Doc may possess phosphorylation activity, it is not clear
whether the phosphorylated target is specific to the toxin, or if it is a result of a block in
translation. Therefore, there are two possible theories for the appearance of the
Doc-dependent phosphorylated product. One possibility is that Doc inhibits translation,
and leads to the indirect phosphorylation of a target molecule, and the other possibility is
that Doc inhibits translation by directly phosphorylating a target molecule. In other
words, the presence of Doc could be responsible for phosphorylation or phosphorylation
might be a result of a block in translation.
Various antibiotics that inhibit translation were incubated in the S30 reaction
mixture with γ[32P] – ATP to determine if the phosphorylation event was specific to Doc.
In this experiment, the pBEST luc plasmid encoding luciferase (Ptacluc) was incubated
with kanamycin, spectinomycin, chloramphenicol, or erythromycin, while the Ptacdoc
plasmid (pRDM037) was used as a positive control. As stated in the introduction, it was
theorized that Doc associates with the 30S ribosomal subunit directly and inhibits
translation elongation by stabilizing the polyribosome in a similar manner to the
antibiotic, hygromycin B. Kanamycin and spectinomycin both bind the 30S ribosomal
subunit, whereas chloramphenicol and erythromycin both bind the 50S ribosomal
subunit. By using these four antibiotics both ribosomal subunits can be tested.
In this experiment, the sample containing Doc was expected to be the only sample
to produce a phosphorylated target. The autoradiogram, seen in Figure 3.6, was
photographed on top of the gel containing the protein ladder, and it showed a band
between 55-35 kDa that was present only in the Doc sample. The difference in the
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molecular weight range from this autoradiogram and the previous one is a difference in
the molecule weight markers used in each experiment. Because none of the samples
containing antibiotics produced a band, the results of this experiment confirmed that
phosphorylation is Doc specific.
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Figure 3.5: Phosphorylation is Doc-specific
To determine if the phosphorylation event was specific to Doc, the pBEST luc plasmid
encoding luciferase (Ptacluc) was co-incubated with γ[32P] – ATP and antibiotics that bind
the 30S or 50S ribosomal subunit and inhibit translation. The Ptacdoc plasmid
(pRDM037), which encodes Doc, was used a positive control. After incubation in the
S30 extract, the samples were precipitated with TCA and denatured in preparation of
SDS PAGE. Then, the gel was run at 75 volts for 110-130 minutes and vacuum dried.
The gel was then exposed to autoradiography film in an autoradiography cassette over 3
nights at room temperature. After this exposure, the film was developed, and the
autoradiogram was photographed on top of the gel containing the pre-stained protein
ladder. The autoradiogram shows a band between 55-35 kDa in the Doc sample. Since
none of the samples containing antibiotics produced a phosphorylated product, this means
that phosphorylation is Doc specific. Refer to Section 2.10 for further experimental
details on the phosphorylation specificity assay.
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3.6 Doc Phosphorylates a Protein
To determine the composition (DNA, RNA, or protein) of the target substrate, the
plasmid encoding Doc (pRDM037) was co-incubated with γ[32P] – ATP in the S30
reaction mixture, and then the samples were treated with DNase, RNase A, or proteinase
K. After treatment with the appropriate degradative enzyme, the molecular weight of the
target should decrease. Thus, the autoradiogram was expected to show a molecular target
that was degraded by one of these enzymes.
To date, all Fic-domain containing proteins that have been shown to catalyze
enzymatic reactions modify small GTPase proteins. Therefore, it was expected that the
target was a protein, and thus treatment with proteinase K would result in a band shift of
the phosphorylated product. The autoradiogram was photographed over the gel
containing the protein ladder, which was used as a molecular weight reference. The
results, observed in Figure 3.6, showed a loss of band signal in the sample treated with
proteinase K. The complete loss of the band rather than a band shift might be due to the
cleavage site of this degradative enzyme. Proteinase K cleaves proteins at aliphatic
amino acids, or amino acids containing nonpolar, hydrophobic side chains, which are
common in proteins. Therefore digestion with proteinase K produces multiple small
fragments that migrate to the bottom of the gel. Nevertheless, the result of a proteinase K
sensitive phosphorylated product confirms that the target is a protein.

58

Figure 3.6: Doc phosphorylates a protein
The Ptacdoc plasmid (pRDM037) was incubated with γ[32P] – ATP in the S30 extract, and
then treated with DNase, RNase, or proteinase K. After incubation and treatment with
degradative enzymes, the samples were precipitated with TCA, denatured, and separated
with SDS PAGE at 75 volts for 110-130 minutes. The gel was then vacuum dried and
exposed to autoradiography film and placed in an autoradiography cassette with an
intensifying scree at room temperature over 3 nights. This protocol is discussed in
Section 2.11. The autoradiogram was photographed on top of the gel containing the
pre-stained protein ladder. Dark bands between 55-35 kDa were present in all the
samples except the sample treated with proteinase K. In fact, the sample treated with
proteinase K showed a complete loss of band signal because digestion with proteinase K,
which cleaves at aliphatic amino acids (nonpolar and hydrophobic), creates many small
fragments that migrate to the bottom of the gel. The loss of signal after treatment with
proteinase K confirms that the phosphorylated product is a protein.
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CHAPTER FOUR

CONCLUSION

The mechanism behind Doc-mediated cell death and the cellular target of the
toxin were unknown (McKinley and Magnuson, 2005). One theory suggested that Doc
inhibits translation elongation by binding directly to the 30S ribosomal subunit
(Lui et al., 2008). Other theories suggest that Doc possesses a catalytic activity similar to
the activities of distant homologs, which include AMPylation and phosphocholination
(Yarbrough et al., 2009; Mukherjee et al., 2011). Doc shows structural similarities to the
Fic family of proteins (Anantharaman and Aravind, 2003). These proteins contain a
Fic-domain that is characterized by eight α helices, a β hairpin, and a conserved sequence
motif that is important for catalytic activity. Certain bacterial Fic-domain containing
proteins, VopS and IbpA, have been shown to AMPylate small GTPases
(Yarbrough et al., 2009; Worby et al., 2009). AnkX, another bacterial protein containing
a Fic-domain, was shown to phosphocholinate a small GTPase (Mukherjee et al., 2011).
Therefore, it is possible that Doc may exhibit AMPylation or phosphocholination activity
(Yarbrough et al., 2009; Mukherjee et al., 2011). However, Doc contains an incomplete
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Fic fold (Garcia-Pino et al., 2008). Specifically, it lacks two α helices and the β hairpin
found in the Fic core of other proteins. Deviations within the Fic fold may result in an
altered function (Goepfert et al., 2013). Thus, while AMPylation and phosphocholination
were good candidates for Doc’s toxicity, there is an alternative possibility for cellular
modification by Doc, which is phosphorylation (Castro-Roa et al., 2013; Cruz et al.,
2014). Phosphorylation is the opposite reaction of AMPylation. This reaction involves
the transfer of the γ phosphate versus the transfer of the α phosphate group
(Yarbrough and Orth, 2009). Phosphorylation is a good possibility because so far the
chemistry of the Fic-domain mediated reactions have involved nucleotides with
high-energy bonds (Castro-Roa et al, 2013; Cruz et al., 2014; Garcia-Pino et al., 2014).
The results of this research confirmed that Doc does inhibit translation. This was
confirmed using [35S] – Met to track the transfer of newly translated proteins in the S30
extract containing plasmids. Using α[32P] – ATP and γ[32P] – ATP to track the transfer of
the α and γ phosphate groups, respectively, the results also confirmed the occurrence of a
Doc-dependent phosphorylation event. This event was determined to be inhibited by the
antitoxin counterpart, and the Doc-dependent phosphorylation event was also determined
to be Doc-specific by blocking translation with various antibiotics. In addition, the
results determined that the dominant phosphorylated product was a protein between
55-35 kDa. Finally, the results showed that Doc appears to be a phosphotransferase
(kinase). Overall, the results of this research showed that Doc utilizes phosphorylation to
effectively modify a protein target. These results were confirmed by the results of two
distinct studies.
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Both of these studies showed that Doc catalyzes a phosphorylation reaction, and
that the toxin targets EF-Tu, a small GTPase involved in the elongation of a polypeptide
during protein synthesis. The studies also showed that the Doc- dependent
phosphorylation of the conserved threonine residue (residue 389) of EF-Tu was sufficient
and necessary to inhibit translation (Castro-Roa et al., 2013; Cruz et al., 2014). Despite
the difference in enzymatic activity, all characterized Fic proteins inactivate essential
GTPases through a post-translation modification (Cruz et al., 2014).
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